{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.73","upperLimit":"0.90","value":"0.83"},{"groupId":"OG001","lowerLimit":"0.67","upperLimit":"0.86","value":"0.78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"description":"Survival from enrollment to first event: relapse/progression, second malignancy, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Regimen I","id":"OG000","title":"Group 2"},{"description":"Regimen II","id":"OG001","title":"Group 3"}],"paramType":"NUMBER","populationDescription":"161 patients began consolidation therapy: 81 Group 2 Regimen I and 80 Group 3 Regimen II.","reportingStatus":"POSTED","timeFrame":"At 3 years from enrollment","title":"Event Free Survival","type":"SECONDARY","unitOfMeasure":"Probability of survival"}